View clinical trials related to Carcinoma, Merkel Cell.
Filter by:CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : - to provide epidemiological, clinical and socio-economic characteristics of patients - to identify new clinical or epidemiological prognostic factors for these rare cancers - to evaluate the impact of various treatments on outcomes
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Background: - Skin disease can have many causes. It can have widespread consequences, and in rare cases can lead to death. Researchers want to determine the causes of various types of skin diseases and find a way to treat them. Objectives: - To determine the causes of various skin diseases and find ways to treat them. Eligibility: - People ages 2 and older who have: - A skin disease or at risk of developing a skin disease OR - A family member of persons with a skin disease - Healthy volunteers ages 2 and older Design: - Participants will be screened under a separate protocol. - Participants may take a survey about how their skin condition affects their quality of life. - Participants will have a medical history and a physical exam including a detailed skin exam. Pictures will be taken of their skin to document any skin disease. - Participants will have specimens collected. This may include: - Several teaspoons of blood taken at each visit - Stool samples - Nail and body fluid (like saliva) samples - Cheek swabs. The inside of the cheek will be scraped for about a minute in each direction to collect cells. - Collection of skin samples with: - A swab (like a Q-tip) - Gently scraping skin to remove the outer layers of cells - Applying and removing 1-inch pieces of tape - Participants may have up to 4 skin biopsies in 12 months, with 4 separate biopsies taken each time. - An area of skin will be numbed with an injection. - A piece of skin the size of a pencil eraser will be removed using a small instrument. - A flat scar usually develops at the biopsy site.